Medicrea to Host Key Opinion Leader Breakfast in New York City for Investors Focused on Advances in the Personalized Spine Market

LYON, France & NEW YORK–(BUSINESS WIRE)– The MEDICREA Group (Alternext Paris: FR0004178572 – ALMED), worldwide
leader pioneering the development and manufacture of personalized
analytical services and implant solutions for the treatment of complex
spinal conditions, today announced that it will host a Key Opinion
Leader breakfast in New York City for investors focused on advances in
the personalized spine market at 8:00 am Eastern Time on Thursday,
December 15, 2016.

The meeting will feature keynote presentations by spine surgeon KOLs
Nicholas Qandah, DO, from the Mohawk Valley Health System, and
Themistocles Protopsaltis, MD, from NYU Langone Medical Center, Bellevue
Hospital, who will provide an overview of the complex spine market and
discuss current and novel approaches to treating complex spinal
conditions.

Members of the Medicrea management team will provide an overview of the
Company’s UNiD™ personalized spinal technology platform of analytical
services and patient-specific implants for the complex spine market,
which received the first ever FDA Clearance for a personalized spinal
treatment modality.

Dr. Nicholas Qandah is a complex spine specialist and the Director of
Neurosurgery at the Mohawk Valley Health System in New Hartford, NY. Dr.
Qandah was previously the Director of the Complex Spine Program for
Neurosurgery and an Assistant Professor of Neurosurgery for the
Residency Program at Virginia Tech Carilion Clinic in Roanoke, VA. In
addition to general neurosurgery, Dr. Qandah treats patients with back
and neck pain, degenerative disc disease, spinal stenosis, and herniated
discs. He has special interest and expertise in minimally invasive spine
surgery, complex spine surgery, and surgery for scoliosis. Dr. Qandah is
a Fellow of the American College of Osteopathic Surgeons and a member of
the Association for Collaborative Spine Research. Dr. Qandah completed
his Neurosurgical Residency training at the Virginia Tech Carilion
Clinic and was subsequently awarded the AO Complex Spine Fellowship in
Orthopedics and Neurosurgery at the prestigious Harborview Medical
Center at the University of Washington in Seattle, WA.

Dr. Themistocles Protopsaltis is an orthopedic spine surgeon at NYU
Langone Medical Center and the Hospital for Joint Diseases. He serves as
Director of Adult Spinal Deformity Surgery and Director of the
Orthopaedic Spine Service at Bellevue Hospital Center in New York, NY.
He is also an Assistant Professor in the Department of Orthopedic
Surgery at NYU School of Medicine. Dr. Protopsaltis is board certified
in orthopedic surgery and is actively involved in many research areas.
Some of his interests include cervical and thoracolumbar spinal
deformity, cervical spondylotic myelopathy surgical outcomes, and
proximal junctional kyphosis avoidance in adult scoliosis patients. He
is a member of the International Spine Study Group, comprised of leading
physicians from multiple academic centers studying cervical and
thoracolumbar spinal deformity surgery. He is also a fellow of the
American Academy of Orthopaedic Surgeons. Dr. Protopsaltis earned his
medical degree at the Columbia University College of Physicians and
Surgeons and completed his orthopedic surgery residency at New York
Presbyterian Hospital. He has completed a spine surgery fellowship at
NYU Langone Hospital for Joint Diseases.

The event is intended for investors, analysts, investment bankers, and
business development professionals only. If you would like to attend in
person, please contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com
to reserve a place.

A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20161215/reg.jsp
and within the Investors section of the Company’s website at www.medicrea.com.

About MEDICREA (www.medicrea.com)

MEDICREA specializes in bringing pre-operative digital planning and pre
and post-operative analytical services to the world of complex spine.
Through the lens of predictive medicine, MEDICREA leads the design,
integrated manufacture, and distribution of 30+ FDA approved implant
technologies, utilized in over 100k spinal surgeries to date. Operating
in a $10 billion marketplace, MEDICREA is an SME with 150 employees
worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The
Company has an ultra-modern manufacturing facility in Lyon, France
housing the development and production of 3D-printed titanium patient-
specific implants.

By leveraging its proprietary software analysis tools with big data and
deep learning technologies supported by an expansive collection of
clinical and scientific data, MEDICREA is well-placed to streamline the
efficiency of spinal care, reducing procedural complications and
limiting time spent in the O.R.

For further information, please visit: medicrea.com.

Connect with MEDICREA:
FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE

MEDICREA is listed on ALTERNEXT Paris ISIN: FR 0004178572 –
Ticker: ALMED

View source version on businesswire.com: http://www.businesswire.com/news/home/20161207006436/en/